Silence, MiReven ink tumor collaboration
LONDON—Silence Therapeutics PLC and MiReven Pty. Ltd. have signed an agreement to assess the delivery potential of Silence's proprietary delivery systems when combined with MiReven's microRNA-based therapeutics. Per the agreement, Silence will develop a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems to evaluate miR-7 in several cancer models. Silence will perform in- vitro and in-vivo studies of the formulated miR-7, and will receive an undisclosed fee.
"MiReven's founding scientists have developed a compelling body of preclinical data supporting the potential of miR-7 to suppress tumor growth, particularly in the many cancers known to be controlled by the EGF receptor signaling pathway, including glioblastoma. MiReven is currently testing drug-like versions of miR-7 in key models of human cancer," Stephen Thompson of MiReven said in a press release.